However, despite promising early results, bintrafusp alfa failed in a phase III trial (NCT03631706) to demonstrate superiority over anti-PD-1 monotherapy in high PD-L1-expressing advanced NSCLC patients [182]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.